The 2022 ACC Expert Consensus Decision Pathway provides practical guidance for the evaluation, management, and return to play of adults with cardiovascular sequelae of COVID-19.
This document provides expert consensus guidance for clinicians evaluating and managing adults with cardiovascular complications following COVID-19 infection.
not correlate particularly well with left ventricular ejection fraction (LVEF), nor with levels of cTn, natriuretic peptides, and C-reactive protein. Classic fi ndings on CMR include increased native T 1 ( fi brosis or in fl ammation) and T 2 (in fl ammation or edema) signals along with myocarditis and other forms of myocardial involvement, pericarditis, new or worsening myocardial ischemia due to obstructive coronary artery disease, microvascular dysfunction, nonischemic cardiomyopathy with involvement of the left and/or right ventricles, thromboembolism, cardiovascular sequelae of pulmonary disease (eg, pulmonary hypertension, right ventricular failure), and arrhythmia (eg, atrial fi brillation, premature ventricular contractions, nonsustained ventricular tachycardia). myocarditis with SARS-CoV-2 infection; 2) unknown rates of adverse outcomes with exercise resumption; and 3) reports of signi fi cant myocardial injury and poor outcomes among some hospitalized patients.
Gluckman et al. (Wed,) conducted a review in Cardiovascular Sequelae of COVID-19. The 2022 ACC Expert Consensus Decision Pathway provides practical guidance for the evaluation, management, and return to play of adults with cardiovascular sequelae of COVID-19.